Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-06-06
1997-06-17
Ramsuer, Robert W.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C07D48704
Patent
active
056398921
ABSTRACT:
There are described compounds of the formula ##STR1## where X is O or S;
REFERENCES:
patent: 2678899 (1954-05-01), Miller et al.
patent: 2909530 (1959-10-01), Rudner et al.
patent: 3457268 (1969-07-01), Frey et al.
patent: 3547945 (1970-12-01), Frey et al.
patent: 3547947 (1970-12-01), Frey et al.
patent: 3551450 (1970-12-01), Frey et al.
patent: 3897451 (1975-07-01), Gassman
patent: 4278667 (1981-07-01), Madison et al.
patent: 4680172 (1987-07-01), Leeson
patent: 4760083 (1988-07-01), Myers et al.
patent: 4765985 (1988-08-01), Leeson
patent: 4791107 (1988-12-01), Hamer et al.
patent: 4831155 (1989-05-01), Brufani et al.
patent: 4857648 (1989-08-01), Broger et al.
patent: 4900748 (1990-02-01), Brossi et al.
patent: 4914102 (1990-04-01), Glamkowski et al.
patent: 4937341 (1990-06-01), Glamkowski et al.
patent: 4971992 (1990-11-01), Glamkowski et al.
patent: 4978673 (1990-12-01), Meroni et al.
patent: 4983616 (1991-01-01), O'Malley et al.
patent: 5077289 (1991-12-01), Glamkowski et al.
patent: 5081117 (1992-01-01), Glamkowski et al.
patent: 5091541 (1992-02-01), O'Malley et al.
patent: 5171750 (1992-12-01), Brossi et al.
patent: 5173497 (1992-12-01), Flanagan
patent: 5177101 (1993-01-01), Glamkowski et al.
patent: 5187165 (1993-02-01), Hamer et al.
patent: 5206260 (1993-04-01), Hichens et al.
patent: 5216017 (1993-06-01), Allen et al.
patent: 5260452 (1993-11-01), Glamkowski et al.
patent: 5264587 (1993-11-01), Flanagan
Atack et al., Comparative Inhibitory Effects of Various Physostigmine Analogs Against Acetyl- and Butyrylcholinesterases, J. Pharmacol. Exp. Therapeutics, 249 (1): 194-202 month not available (1989).
Bartolini et al., Eseroline: A New Antinociceptive Agent Derived from Physostigmine with Opiate Receptor Agonist Properties. Experimental In Vivo and In Vitro Studies on Cats and Rodents, Neurosci. Lett., 25: 179-183 Sep. (1981).
Berge et al. Pharmaceutical Salts, J. Pharm. Sci., 66:1-19 Jan. (1977).
Bores et al., HP 290: A Potent, Orally Active Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease, Soc. Neurosci. Abstr., 17(1): 699 Nov. (1991).
Brossi et al., Chemical Abstracts 109: 740 no month available (1988), Abstract Nos. 190632x and 190633y.
Brzostowska et al., Phenylcarbamates of (-)-Eseroline, (-)-N.sup.1 -Noreseroline and (-)-Physovenol: Selective Inhibitors of Acetyl and, or Butyrylcholinesterase, Med. Chem. Res., 2: 238-246 no month avialable (1992).
Brufani et al., Anticholinesterase Activity of a New Carbamate, Heptylphysostigmine, in View of Its Use in Patients with Alzheimer-type Dementia, Eur. J. Biochem., 157: 115-120 May (1986).
Chemical Abstracts, Section 25, Benzene, Its Derivatives, And Condensed Benzenoid Compounds, 108(25): 535-543 no month available (1988).
Colvin, Silicon in Organic Synthesis, Butterworths Monographs in Chemistry and Chemical Engineering, Chapter 10, Butterworths (London) no month avialable (1981).
Ellis et al., Studies on Physostigmine and Related Substances.sup.1 , III. Breakdown Products of Physostigmine; Their Inhibitory Effect on Cholinesterase and Their Pharmacological Action, J. Pharm. Exp. Ther., 79: 309-319 no month available (1943).
Galli et al., Inhibition of [.sup.3 H] naloxone Binding in Homogenates of Rat Brain by Eseroline, a Drug, with Analgesic Activity, Related to Physostigmine, J. Pharm. Pharmacol. (Communications), 31: 784-786 Nov. (1979).
Giacobini et al., Pharmacokinetics and Pharmacodynamics of Physostigmine After Intravenous Administration in Beagle Dogs, Neuropharmacology, 831-836 no month avialable (1987).
Gorman et al., Comparison of the Cardiovascular Effects of HP 290 and Heptylstigmine (HEP), New Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Meeting Abstract No. 7210, FASEB Annual Meeting, Atlanta, GA, Apr., 1991.
Gould, Salt Selection for Basic Drugs, Int. J. Pharmaceutics, 33: 201-217 no month avialable (1986).
Hamer et al., HP 290: A New, Potent Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease, Meeting Abstract No. 74, American Chemical Society Division of Medicinal Chemistry, Atlanta, GA, Apr., 1991.
Hamer et al., Chemical Abstracts 108: 596 no month avialable (1988), Abstract No. 221937m.
Howard et al., HP 290: A Potential Alzheimer's Therapeutic Agent with Reduced Cardiovascular Liability, Soc. Neurosci. Abstr., 17 (1): 699 Nov. (1991) .
Isaksson and Kissinger, Metabolism of Physostigmine in Mouse Liver Microsomal Incubations Studied by Liquid Chromatogrpahy with Dual-Electrode Amperometric Detection, J. Chromatography, 419: 165-175 no month avialable (1987).
Julian and Pikl, Studies in the Indole Series. IV. The Synthesis of d,1-Eserethole, J. Am. Chem. Soc., 57: 563-566 Mar. (1935).
Julian and Pikl, Studies in the Indole Series. V. The Complete Synthesis of Physostygmine (Eserine), J. Am. Chem. Soc., 57: 755-757 Apr. (1935).
King and Robinson, Experiments on the Synthesis of Physostigmine (Eserine). Part XI. The Later Phases of the Synthetical Investigations, J. Chem. Soc., 755-759 no month available (1935).
Merck Index, The, Eleventh Edition no month avialable (1989), pp. 1172-1173.
New Candidates for Treating Alzheimer's, C & E News, Apr. 29, 1991, p. 28.
Polonovski, Bull. Chem. Soc. France, 19: 47-59 no month available (1916).
Polonovski, Chemical Abstracts, 10: 1329 no month available (1916).
Robinson, Alkaloids of the Calabar Bean, in: The Alkaloids, Manske, ed., Chapter 5, pp. 383-400 no month available (1968).
Robinson, Synthesis of dl-Eseramine.sup.1, Chem. & Ind., Jan. 9, 1965, pp. 87-88.
Robinson and Robinson, The Anti-Acetylcholinesterase Activities of the Alkaloids of Physostigma veneosum Seeds, J. Pharm. Pharmac., 20(Suppl.): 213S-217S no month available (1968).
Roth and Fenner, in: Pharmazeutische Chemie III: Arzneistoffe Struktur- Bioreaktivitat-Wirkungsbezogene Eigenschaften, Verlag (Stuttgart), no month available 1988, pp. 390-395.
Salway, Researches on the Constitution of Physostigmine Part I, J. Chem. Soc., 101: 978-989 (1912).
Schonenberger and Brossi, Fragmentation of Optically Active (1-Phenylethyl)- and (1-Naphthylethy1) ureas in Refluxing Alcohols: Easy Preparation of Optically Active Amines of High Optical Purity, Helvetica Chimica Acta, 69: 1486-1497 no month available (1986).
Schonenberger et al., Comparison of (-)-Eseroline with (-)-Eseroline and Hihydroseco Analogues in Antinociceptive Assays: Confirmation of Rubreserine Structure by X-ray Analysis, J. Med. Chem., 29: 2268-2273 no month available (1986).
Schonenberger et al., Preparation of Optically Active Secondary Amines by Thermal Decomposition of (Methylbenzyl)urea Analogs: Absolute Configuration of (+)-and (-)-Mecamylanime, Helvetica Chimica Acta, 69: 283-287 a month available (1986).
Sibi et al., The Directed Ortho Lithiation of O-Aryl Carbamates. An Anionic Equivalent of the Fries Rearrangement, J. Org. Chem., 48: 1935-1937 no month available (1983).
Somani and Khalique, Pharmacokinetics and Pharmacodynamics of Physostigmine in the Rat After Intravenous Administration, Drug Metabolism and Disposition, 15(5): 627-633 (1987).
Somani, Pharmacokinetics and Pharmacodynamics of Physostigmine in the Rat After Oral Administration, Biopharmaceutics & Drug Disposition, 10: 187-203 no month available (1989).
Stern et al., Effects of Oral Physostigmine in Alzheimer's Disease, Ann. Neurol., 22: 306-310 Sep. (1987).
Sumimoto Pharm. Co., Ltd. (Japan), SM-10888: Agent for Cognition Disorders; Acetylcholinesterase Inhibitor, Drugs of the Future, 16(1): 33-36 no month available (1991).
Trommer et al., Thioeserin, das Thioanalogon des Eserins, Arch. Pharm., 309: 631-638 no month available (1976).
Unni and Somani, Hepatic and Muscle Clearance of Physostigmine in the Rat, Drug Metabolism and Disposition, 14(2): 183-189 no month available (1986).
Unni et al., Kinetics of Cholinesterase Inhibition by Eptastigmine in Man, Eur. J. Clin. Pharmacol., 41:83-84 no month available (1991).
Yu et al., Synthesis and Anticholinesterase Activity of (-) -N.sup.1 -Norphysostigmine, (-)-Eseramine and Other N(1)-Substituted Analogues of (-) -Physostigmine, J. Med. Chem., 31 (12) : 2297-230
Chiang Yulin
Glamkowski Edward J.
Hamer R. Richard L.
Helsley Grover C.
Hoechst-Marion-Roussel, Inc.
Ramsuer Robert W.
LandOfFree
Memory enhancing and analgesic 1,2,3,3a,8,8a,-hexahydro-3a,8(and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Memory enhancing and analgesic 1,2,3,3a,8,8a,-hexahydro-3a,8(and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Memory enhancing and analgesic 1,2,3,3a,8,8a,-hexahydro-3a,8(and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2158988